Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BB Anti-androgens
L02BB04 Enzalutamide
D10218 Enzalutamide (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antiandrogens
Enzalutamide
D10218 Enzalutamide (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10218 Enzalutamide (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01591 Androgen receptor antagonist
DG01624 Flutamide-type antiandrogen
D10218 Enzalutamide
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D10218 Enzalutamide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10218 Enzalutamide
Drug classes [BR:br08332]
Antineoplastic
DG01591 Androgen receptor antagonist
D10218 Enzalutamide
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
3-Ketosteroid receptor
NR3C4 (AR)
D10218 Enzalutamide (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10218
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10218
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10218
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10218
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10218